Recombinant Cynomolgus IL7R Protein, His-tagged

• Cat.No.: IL7R-1231C
• Product Overview: Recombinant cynomolgus IL7R (NP_001271837.1) (Met1-Pro235) was expressed with a polyhistidine tag at the C-terminus.

Specification

• Source: HEK293
• Species: Cynomolgus
• Tag: His
• Predicted N Terminal: Glu 21
• Form: Lyophilized from sterile PBS, pH 7.4, 5%~8% trehalose and mannitol.
• Molecular Mass: The recombinant IL7R consists 226 amino acids and predicts a molecular mass of 26.3 kDa.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: >85 % as determined by SDS-PAGE.
• Stability: Samples are stable for up to twelve months from date of receipt at -70ºC.
• Storage: Store it under sterile conditions at -20ºC~-70ºC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: IL7R interleukin 7 receptor [ Macaca fascicularis ]
• Official Symbol: IL7R
• Synonyms: IL7Ra; IL-7RA; IL-7 receptor subunit alpha; IL-7R subunit alpha; IL-7R-alpha
• Gene ID: 102143679
• mRNA Refseq: NM_001284908
• Protein Refseq: NP_001271837
• UniProt ID: Q38IC7
• Chromosome Location: chromosome: 6
• Pathway: Cytokine-cytokine receptor interaction, organism-specific biosystem; FoxO signaling pathway, organism-specific biosystem; PI3K-Akt signaling pathway, organism-specific biosystem

Reviews

02/21/2022

The pharmacodynamic parameters of IL7R were good.

02/01/2022

IL7R has good compatibility and stability with various excipients.

09/30/2021

Strong potential to desensitize specific allergens.

Q&As

What is the prospect of recombinant IL7R in tumor immunotherapy?

IL7R is a potential drug for tumor immunotherapy, which is expected to enhance anti-tumor immune response, but further research and clinical demonstration are still needed.

Is there any research showing that recombinant IL7R can be used to treat immune system failure?

Recombinant IL7R can enhance the body's immune response, but there is not enough evidence to show that it can be used to treat immune system failure.

How the role of IL7R in immunotherapy?

It can enhance the immune response ability of T cells and improve the immune response of the body, so as to have a therapeutic effect on immune-related diseases.

Does IL7R have synergistic effects with immune checkpoint inhibitors?

There is no clear evidence that IL7R has a synergistic effect with immune checkpoint inhibitors, but this research direction deserves further exploration.

Which diseases is IL7R associated with?

IL7R has been associated with immune-related diseases such as cancer, inflammatory bowel disease, and rheumatoid arthritis.

Is there any restriction on the use of IL7R?

The use of IL7R is patient specific and may be subject to some limitations, such as pregnant and lactating women and patients with certain immune-related diseases.